Liu J - Search Results

1

GdX inhibits the occurrence and progression of breast cancer by negatively modulating the activity of STAT3.

Chen Z, Xu L, Lin S, Huang H, Long Q, Liu J. Chen Z, et al. Among authors: liu j. Cancer Biol Ther. 2024 Dec 31;25(1):2420383. doi: 10.1080/15384047.2024.2420383. Epub 2024 Nov 2. Cancer Biol Ther. 2024. PMID: 39487760 Free PMC article.

2

Cell adhesion molecule 4 suppresses cell growth and metastasis by inhibiting the Akt signaling pathway in non-small cell lung cancer.

Luo F, Zhao Y, Liu J. Luo F, et al. Among authors: liu j. Int J Biochem Cell Biol. 2020 Jun;123:105750. doi: 10.1016/j.biocel.2020.105750. Epub 2020 Apr 20. Int J Biochem Cell Biol. 2020. PMID: 32325280

3

Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.

Tian L, Shen D, Li X, Shan X, Wang X, Yan Q, Liu J. Tian L, et al. Among authors: liu j. Oncotarget. 2016 Jan 12;7(2):1619-32. doi: 10.18632/oncotarget.6451. Oncotarget. 2016. PMID: 26636541 Free PMC article.

4

Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness.

Wang J, Tian L, Khan MN, Zhang L, Chen Q, Zhao Y, Yan Q, Fu L, Liu J. Wang J, et al. Among authors: liu j. Cancer Lett. 2018 Feb 28;415:73-85. doi: 10.1016/j.canlet.2017.11.037. Epub 2017 Dec 2. Cancer Lett. 2018. PMID: 29199005

5

USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.

Lu C, Ning Z, Wang A, Chen D, Liu X, Xia T, Tekcham DS, Wang W, Li T, Liu X, Liu J, Qi H, Luo H, Du J, Ma C, Yan Q, Liu J, Xu G, Piao HL, Tan G. Lu C, et al. Among authors: liu j, liu x. Cancer Lett. 2018 Nov 1;436:139-148. doi: 10.1016/j.canlet.2018.07.032. Epub 2018 Jul 26. Cancer Lett. 2018. PMID: 30056112

6

SND1 promotes the proliferation of osteosarcoma cells by upregulating COX‑2/PGE2 expression via activation of NF‑κB.

Zhou M, Wang A, Yin B, Wu D, Han S, Zhang W, Liu J, Sun K. Zhou M, et al. Among authors: liu j. Oncol Rep. 2019 Jan;41(1):579-589. doi: 10.3892/or.2018.6822. Epub 2018 Oct 24. Oncol Rep. 2019. PMID: 30365124

7

Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.

Zhang L, Shan X, Chen Q, Xu D, Fan X, Yu M, Yan Q, Liu J. Zhang L, et al. Among authors: liu j. J Cell Physiol. 2019 Dec;234(12):22207-22219. doi: 10.1002/jcp.28788. Epub 2019 Jun 13. J Cell Physiol. 2019. PMID: 31192452

8

Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.

Zhang B, Zhang X, Zhou T, Liu J. Zhang B, et al. Among authors: liu j. Cancer Biol Ther. 2015;16(2):215-8. doi: 10.4161/15384047.2014.962318. Cancer Biol Ther. 2015. PMID: 25668362 Free PMC article. Review.

9

USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.

Ning Z, Wang A, Liang J, Xie Y, Liu J, Feng L, Yan Q, Wang Z. Ning Z, et al. Among authors: liu j. Int J Oncol. 2014 Oct;45(4):1594-608. doi: 10.3892/ijo.2014.2531. Epub 2014 Jul 3. Int J Oncol. 2014. PMID: 24993031

10

Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression.

Shan X, Aziz F, Tian LL, Wang XQ, Yan Q, Liu JW. Shan X, et al. Int J Oncol. 2015 Apr;46(4):1667-76. doi: 10.3892/ijo.2015.2886. Epub 2015 Feb 10. Int J Oncol. 2015. PMID: 25672851 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

143,969 results

Search Page

Filters